Precision AI company Nucleai has is partnering with biotech company Protean BioDiagnostics, to commercialise advanced cancer diagnostic technology.
Nucleai and Protean BioDiagnostics are launching a co-branded campaign, Protean QA Service Enhancement powered by Nucleai, that will pair Nucleai’s AI services with Protean BioDiagnostic laboratories’ diagnostic tools. This service will be deployed in labs, hospitals, and urology centres across the US.
Nucleai is a clinically oriented AI company for pathologists to improve diagnosis. It provides a suite of AI-based solutions for cancer biopsies relating to gastrointestinal, breast and prostate tissue analysis and an effective pipeline for supporting additional indications.
Avi Veidman, CEO of Nucleai, said: “We are thrilled to partner with Protean BioDiagnostics, a company who shares our mission: to use operational AI to improve the existing standard of care for cancer patients. Their strong network is a great springboard for Nucleai and will open new opportunities for mutual development of precision medicine solutions including prediction and prognosis tools.”
Research shows that by 2030 the number of active pathologists in the US may drop by 30% compared to 2010 levels, and coupled with an increasing demand for biopsies, the pathology field is ripe for disruption. Protean BioDiagnostics will now have access to the most advanced AI technology on the market, backed by over 20 million slides and a team that boasts over 100 years of cumulative experience in AI, machine learning and machine vision.
Dr. Anthony Magliocco, founder and president of Protean BioDiagnostics said: “Our mission at Protean BioDiagnostics is to offer the most advanced and personalized oncology technology to help cancer patients and their doctors in the most effective ways possible. We are very excited to collaborate with Nucleai to combine our molecular capabilities with their advanced image analysis solution to develop leading solutions in the precision medicine area.”
Protean BioDiagnostics’ expertise on the molecular aspects of precision medicine will help Nucleai develop and scale a precision medicine solution which will be added to the company’s existing technology platforms.